SCaBER Xenograft Model Service for Bladder Cancer

The SCaBER xenograft model offers a robust, clinically relevant platform for evaluating therapeutic strategies against basal-type bladder squamous cell carcinoma, one of the most aggressive molecular subtypes of bladder cancer. Alfa Cytology specializes in constructing high-fidelity SCaBER xenograft models, providing comprehensive preclinical services that span from tumor establishment and in vivo monitoring to pharmacodynamic and efficacy endpoint analysis, ensuring your compound is evaluated in a biologically faithful setting.

Overview of SCaBER Xenograft Model for Bladder Cancer

SCaBER is an established human bladder cancer cell line originally derived from a documented squamous cell carcinoma of the urinary bladder. It retains the characteristic morphology of its tumor of origin, including features of squamous differentiation such as intercellular bridges and keratin pearls, making it a representative model for basal-subtype bladder cancer. In xenograft settings, SCaBER tumors exhibit high expression of basal markers (KRT5/6, KRT14, EGFR) and epithelial-mesenchymal transition (EMT) markers, while showing low or absent luminal marker expression (FOXA1, GATA3, uroplakins). This molecular profile aligns SCaBER with the basal-squamous molecular subtype identified in The Cancer Genome Atlas (TCGA) classification, a subtype associated with aggressive disease, therapeutic resistance, and poor prognosis in patients.

SCaBER xenografts have been extensively utilized in orthotopic and subcutaneous implantation studies to investigate tumor microenvironment interactions, drug resistance mechanisms, and subtype-specific therapeutic vulnerabilities. The model is particularly valuable for testing anti-EGFR based regimens, Wnt/beta-catenin pathway inhibitors, and combination chemotherapies, given the cell line's documented enrichment in these signaling pathways. Its consistent tumorigenicity in immunodeficient mouse strains and retention of basal molecular features make SCaBER a cornerstone model for preclinical bladder cancer research focused on aggressive, non-luminal disease phenotypes.

Figure 1. Heatmap illustrating the supervised hierarchical clustering of basal and luminal markersamong the 9 cell lines. (Mokkapati, S, et al., 2025)

Cell Line Information: SCaBER

The following table summarizes the key characteristics and technical specifications of the SCaBER cell line for xenograft model development.

Our Services

Alfa Cytology delivers end-to-end SCaBER xenograft model services tailored to your preclinical pipeline. From precise cell line authentication and orthotopic or subcutaneous tumor establishment to longitudinal tumor monitoring via bioluminescence imaging, histopathological validation, and multi-parameter pharmacodynamic analysis, our integrated platform ensures rigorous, reproducible data generation. Whether you are evaluating novel anti-EGFR agents, Wnt pathway inhibitors, or combination chemotherapy regimens, Alfa Cytology provides the technical depth and project management expertise to accelerate your bladder cancer therapeutic development program.

Workflow of SCaBER Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to construct SCaBER xenograft models, ensuring reproducible tumor growth and reliable pharmacological readouts. The process integrates cell line quality verification, strategic implantation, continuous health and tumor monitoring, and comprehensive endpoint analysis.

1. Cell Line Authentication & Preparation: SCaBER cells are authenticated via STR profiling and confirmed mycoplasma-free. Cells are expanded under standardized culture conditions (RPMI 1640 + 10% FBS) and harvested at logarithmic growth phase for optimal viability.
2. Mouse Strain Selection & Acclimation: Immunodeficient strains such as NSG or BALB/c nude mice (6--8 weeks old) are selected based on study objectives. Animals are acclimated for at least 5--7 days under pathogen-free conditions with controlled environmental parameters.
3. Tumor Cell Inoculation: For subcutaneous models, 2.0 x 10^5 to 1.0 x 10^6 SCaBER cells are resuspended in a 1:1 mixture of serum-free medium and Matrigel and injected into the flank. For orthotopic models, luciferase-tagged cells are instilled into the bladder wall or lumen via surgical or catheter-based techniques.
4. Tumor Establishment Monitoring: Tumor growth is monitored via caliper measurements (subcutaneous) or bioluminescence imaging (orthotopic) at defined intervals. Body weight and clinical signs are recorded to assess general health and detect early adverse effects.
5. Treatment Administration & Dosing: Once tumors reach a target volume (typically 100--200 mm^3 for subcutaneous models), animals are randomized into treatment and vehicle control groups. Test articles are administered according to the predefined dosing schedule (PO, IP, IV, or intravesical).
6. Longitudinal Efficacy Assessment: Tumor dimensions are measured twice weekly; bioluminescence signal intensity is quantified for orthotopic studies. Tumor growth inhibition (TGI) and tumor growth delay (TGD) are calculated relative to vehicle controls.
7. Endpoint Analysis & Tissue Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC for Ki67, KRT14, EGFR, cleaved caspase-3), RNA/DNA extraction for molecular profiling, and plasma/tissue pharmacokinetic analysis if required.
8. Data Compilation & Reporting: All raw data, statistical analyses, and representative images are compiled into a comprehensive study report with interpretation of pharmacodynamic and efficacy findings, ready for regulatory or publication use.

Figure 2. SCaBER xenograft model construction workflow.

Case Study-SCaBER Xenograft Model Development

Alfa Cytology has successfully established and validated SCaBER xenograft models for multiple preclinical programs targeting basal-squamous bladder cancer. In a representative engagement, SCaBER tumors were established in NSG mice via subcutaneous implantation, achieving consistent tumor take rates and reproducible growth kinetics suitable for compound efficacy screening. Pharmacodynamic analyses demonstrated robust target engagement and measurable anti-tumor activity across multiple mechanistic classes, including EGFR inhibitors and DNA-damaging agents. Detailed efficacy data, tumor growth curves, histopathological scoring, and biomarker modulation results are available upon request under confidentiality agreements. Please contact our business development team to discuss how these validated datasets can support your specific program requirements.

Why Choose Alfa Cytology?

Alfa Cytology combines deep expertise in bladder cancer biology with rigorous operational standards to deliver xenograft models that generate actionable preclinical insights. Our differentiated capabilities ensure your program benefits from both scientific sophistication and operational excellence.

• Molecularly characterized SCaBER models with confirmed basal-squamous subtype identity and authenticated cell line provenance.
• Flexible implantation strategies including subcutaneous, orthotopic, and patient-derived xenograft (PDX) hybrid approaches.
• Integrated in vivo imaging infrastructure (bioluminescence, MRI-compatible small animal imaging) for real-time tumor monitoring.
• Comprehensive histopathology and biomarker analysis suite with custom IHC panels for basal, luminal, and EMT markers.
• Dedicated project management with tailored study designs, adaptive dosing schedules, and rapid turnaround on feasibility assessments.
• Strict quality control and compliance with IACUC guidelines, ensuring reproducible data and audit-ready documentation.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated SCaBER xenograft model? Contact us today to discuss your project specifications, request a feasibility proposal, or schedule a consultation with our scientific team. Please reach out to us today via our inquiry form or email to learn more about our SCaBER Xenograft Model services.

For research use only. Not intended for any clinical use.